Researchers at the University of Birmingham have made a breakthrough in the understanding of how our genetic make-up can impact on the activity of the immune system and our ability to fight cancer.
Faron Pharmaceuticals (Faron), the clinical stage biopharmaceutical company, has signed an agreement with the University to initiate a liver cancer program testing Clevegen, Faron's immuno switch antibody, in clinical trials.
The Cancer Research UK Birmingham Centre, established on 1 April 2017, will bring together researchers specialising in understanding cancer genetics, how cancer avoids our body's defences and the role viruses play in certain cancers.
Researchers at the University of Birmingham have developed and validated a new electronic virtual chromoendoscopy (EVC) score that could reflect the full spectrum of mucosal and vascular changes, including mucosal healing in ulcerative colitis.
A new study has identified novel mechanisms whereby T cells may be able to distinguish an emerging class of targets specifically increased on cancer cells.
The NIHR Birmingham Biomedical Research Centre (BRC) opened on 1 April 2017 with the aim of accelerating the access to, and adoption of, drugs, devices and diagnostics tests for patients living with chronic inflammatory disease, driven by cutting edge experimental medicine.
A global study involving researchers from the University of Birmingham has identified key risk groups of liver disease patients to indicate their survival estimates and likelihood of developing cancer.
The University of Birmingham has purchased 9.9acres of land in the Selly Oak area to develop a brand new Life Sciences Park.
The University of Birmingham is currently recruiting early career researchers of exceptional ability to join our "Birmingham Fellows Programme".
A new clinical trial is looking at the feasibility of using 'discarded' livers to tackle the shortage of liver donors, and help decrease waiting times for patients on the transplant register.